Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Eagle Pharmaceuticals, Inc. EGRX
$20.49
-$0.46 (-2.24%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
269534520.00000000
-
week52high
49.00
-
week52low
20.03
-
Revenue
316610000
-
P/E TTM
9
-
Beta
0.90968800
-
EPS
2.76000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Neutral | Neutral | 02 мар 2020 г. |
| Mizuho | Neutral | Neutral | 22 мар 2019 г. |
| PiperJaffray | Neutral | Overweight | 31 окт 2018 г. |
| Cantor Fitzgerald | Overweight | Overweight | 21 сент 2018 г. |
| Cantor Fitzgerald | Overweight | Overweight | 12 июн 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Cahill Brian Joseph | D | 30871 | 601 | 30 янв 2023 г. |
| Tarriff Scott | D | 1572147 | 3732 | 23 янв 2023 г. |
| Tarriff Scott | D | 1575879 | 3827 | 05 янв 2023 г. |
| Cahill Brian Joseph | D | 31472 | 734 | 05 янв 2023 г. |
| Cahill Brian Joseph | D | 32206 | 461 | 19 дек 2022 г. |
| Edlin Richard A. | D | 22600 | 6800 | 06 сент 2022 г. |
| BORIO LUCIANA | A | 11200 | 11200 | 28 февр 2022 г. |
| Cahill Brian Joseph | A | 32667 | 8000 | 28 февр 2022 г. |
| Moran Michael Shawn | A | 32115 | 10400 | 28 февр 2022 г. |
| Simpson Jennifer K. | A | 11200 | 11200 | 28 февр 2022 г. |
Новостная лента
Eagle Pharmaceuticals to Host First Quarter 2023 Financial Results on May 9, 2023
GlobeNewsWire
27 апр 2023 г. в 16:30
WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2023 financial results on Tuesday, May 9, 2023, before the market opens.
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates
Zacks Investment Research
13 мар 2023 г. в 09:12
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference
GlobeNewsWire
09 мар 2023 г. в 16:10
WOODCLIFF LAKE, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference, in Miami, FL, as follows:
Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
GlobeNewsWire
03 мар 2023 г. в 06:50
WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:
Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?
Zacks Investment Research
29 дек 2022 г. в 11:17
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.